PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.15
Negative D/E while Healthcare median is 0.03. Seth Klarman would scrutinize balance sheet quality and look for restructuring potential.
0.94
Very conservative net debt at 50-90% of Healthcare median of 1.37. Philip Fisher would suggest checking if this conservatism supports R&D and growth investments.
-7936.02
Negative coverage while Healthcare median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
0.78
Current ratio below 50% of Healthcare median of 2.60. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.